Tarcocimab and the ABCD Platform’s high molecular weight increases its human ocular half - life, extending its therapeutic benefit in the eye 27 Each dot represents the ocular half - life from one individual patient. Blue dots are tarcocimab from the Phase 1b study of tarcocimab in patients with wet AMD, DME and RVO. Gray dots are faricimab from Genentech, Inc. PK and ER of faricimab, Report # 1105763